All lobbying filings

ARENTFOX SCHIFF LLP

ARENTFOX SCHIFF LLP filed a Q3 report for ORGANOGENESIS INC. on October 16, 2025, reporting $70,000 in lobbying income.

Lobbying for ORGANOGENESIS INC. · Biotech company

All filings by ARENTFOX SCHIFF LLP · Everything ORGANOGENESIS INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 16, 2025

Income

$70,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 2

BLAKE THELANDER New on this filing

Previously held: Health Policy Advisor/Legislative Director, Rep. Mariannette Miller-Meeks (2023-2025), Staff Assistant/Legislative Assistant/Senior Legislative Assistant, Rep. Jefferson Van Drew (2020-2023), Intern, Rep. Ralph Norman (2019-2019)
KELSEY GRISWOLD-BERGER New on this filing

Previously held: Sr Policy Advisor, Sen McCormick (2025); LA, Sen Burr (2021-23); Leg Dir, Rep C Smith (2018-21); Leg Dir, Rep Pittenger (2018); Leg Dir, Rep Blum (2017-18); LA, Rep Perry (2015-17); LA (2014-15), LC/Press Asst (2011-14), SA (2011), Rep Reed

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill NOTE: Elizabeth Horner, a lobbyist for the listed client, did not lobby, and did not make any communication to, appearance before, or lobbying contact with, the Senate, any Senator or any officer or employee of the Senate, on behalf of the listed client, until after her ban expired on August 12, 2025.

Health Issues

Food and Drug Administration policy on chronic wound healing products

Bills named in this filing 1

S. 2561
Skin Substitute Access and Payment Reform Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.